Dama da Kulawa da Lafiya na Lymphoma Ba-Hodgkin
Hasarin ci gaba da lymphoma ne aka kara girma bayan m kwayarwa misali misali koda transplants, hanta transplants, zuciya transplants ko ƙwayoyin transplants. Wadannan lymphomas suna dauke da lafiyar "cututtukan lymphoproliferative post-transplant" ko PTLDs.
Yaya yawancin Lymphoma bayan Organ Transplant?
PTLD ya ƙunshi nau'o'in lymphoproliferative da yawa a jikin kwaya mai karfi ko hematopoietic transplantation (HSCT) kuma zai iya faruwa kashi 10 cikin dari na manya bayan dasawa.
An kuma yi amfani da iyakar kashi 1 zuwa 20 cikin kimanin kimanin kashi 20 zuwa kashi 20 cikin dari.
Me yasa Lymphomas ke faruwa bayan kwayar bishiyar?
Kwayoyin lymphomas na dashi suna kusan alaka da kamuwa da cutar ta Epstein Barr Virus (EBV) . Rashin kamuwa da cutar ta Epstein Barr yana haifar da canji na B-kwayoyin (irin lymphocyte ko jini mai tsabta) wanda ya zama cancerous. A cikin al'ada al'amuran wasu kwayoyin halittar kwayoyin cuta na iya magance cutar ta EBV, amma ga mutanen da ke da suturar kwayoyin halitta, manyan maganin magungunan da ke hana tsarin rigakafi dole ne a gudanar. Ba tare da wani abu don kula da kamuwa da cuta ba, chances na bunkasa ƙwayar lymphomas.
Wadanne abubuwa ne suke ƙaddamar haɗari na Lymphoma Post-Transplant?
Babban dalilai biyu da ke ƙayyade chances na samun lymphoma su ne:
- Nawa ne ake buƙatar maganin rigakafin rigakafi - Da yawancin maganin rigakafi, mafi yawan samuwa na EBV.
- Matsayi na EBV serology na mai karɓa na dashi - Idan mutum ya rigaya ya kamu da cutar ta EBV (yana da tarihi na kasancewa daya) abu ne mai yiwuwa shine jiki ya tuna da kamuwa da cuta kuma jini yana da sunadarai na musamman da ake kira antibodies wanda zai iya gano da kuma kashe cutar. Ana iya gwada wannan ta hanyar shan samfurin jini.
Ta Yaya Zamu Yi Tsira da Lissafi?
A matsakaici, idan PTLD zai faru, lokaci mai mahimmanci don yin haka shi ne kimanin watanni 6 bayan an dasa shi a cikin marasa lafiya mai kwakwalwa da kuma watanni 2-3 a cikin masu karɓar HSCT, amma an bayar da rahotanni da sati daya da 1 a matsayin marigayi na shekaru 10 bayan dashi.
Siffofin lymphomas na dashi suna da bambanci daga sababbin lymphomas wadanda ba na Hodgkin . Kwayoyin ciwon daji na wannan lymphoma suna daga cikin nau'i daban daban da kuma girma. Duk da yake mafi yawan marasa lafiya suna da hannu wajen ƙwayar lymph, sauran kwayoyin suna da rinjaye sosai - abin da ake kira 'extranodal' . Wadannan sun hada da kwakwalwa, huhu da kuma hanji. Ƙungiyar da aka sassauki za ta iya shiga.
Yaya aka yi Amfani da Lymphoma Tsarin Gida?
Duk lokacin da zai yiwu, dole ne a rage ko tsayar da rigakafin rigakafi. A wa] anda ke da} wararrun ƙwayoyin cutar, tiyata ko radiation za a iya ƙoƙari. Idan ba haka ba, hanyar farko na magani shine yawancin Rituxan (rituximab) , wanda ya saba da kwayar cutar lymphoma. Sai kawai lokacin da wannan ya kasa cin nasara ne a kokarin gwaje-gwaje. Chemotherapy an dakatar da shi har sai ya zama dole kamar yadda mutane da yawa wadanda ba su da kariya ba zai iya kara haɗarin cututtuka .
A wa anda ke samar da kwayoyin lymphomas bayan sassaukar ɓarwon nama, mai ba da taimako ga yaduwar jini zai iya zama tasiri sosai.
Mene ne sakamakon tare da Lymphomas na dashi?
Gaba ɗaya, PTLD shine babban mawuyacin rashin lafiya da mutuwa, tarihi tare da yawan mace-mace da aka wallafa har zuwa kashi 40-70 cikin marasa lafiya tare da sassauran kwayoyin halitta da kuma kashi 90 a cikin marasa lafiya bayan HSCT. Hanyoyin da ba na Hodgkin da ke faruwa bayan sassan bishiyoyin suna da mummunan sakamako fiye da sauran NHLs. Wani adadi wanda aka wallafa shi ne cewa kimanin 60-80% na ƙarshe ya ci nasara ga lymphoma. Duk da haka, yin amfani da Rituxan ya canza saurin rayuwa, wasu kuma suna yin tafiya mai yawa kuma zasu iya warkewa.
Hada wasu gabobin, musamman ma kwakwalwa, yana da matsala mara kyau.
Sources:
Shi, G., Wang, C., Tan, H., da S. Ya. Rituximab bayan bayanan autologous na sassaucin kwayar halitta ya bunkasa rayuwa na marasa lafiya B-cell lymphoma. Ayyukan Juyewa . 2015. 47 (2): 517-22.
Katabathina, V., Menias, C., Pickhardt, P., Lubner, M., da S. Prasad. Rarraban Immunosuppressive Far a cikin Organ Organic Transplantation. Radiology Clinics na Arewacin Amirka . 2016 54 (2): 303-19.
> Metser U, Lo G. FDG-PET / CT a cikin ƙwayar cutar lymphoproliferative a ciki. Br J Radiol . 2016; 89 (1057): 20150844.
Petrara, M., Giunco, S., Serraino, D., Dolcetti, R., da A. De Rossi. Cutar cutar lymphoproliferative post-transplant: daga cututtuka don maganin cututtuka. Lissafin Wuta . 2015. 369 (1): 37-44.